Unknown

Dataset Information

0

Time From Imaging to Endovascular Reperfusion Predicts Outcome in Acute Stroke.


ABSTRACT: BACKGROUND AND PURPOSE:This study aims to describe the relationship between computed tomographic (CT) perfusion (CTP)-to-reperfusion time and clinical and radiological outcomes, in a cohort of patients who achieve successful reperfusion for acute ischemic stroke. METHODS:We included data from the CRISP (Computed Tomographic Perfusion to Predict Response in Ischemic Stroke Project) in which all patients underwent a baseline CTP scan before endovascular therapy. Patients were included if they had a mismatch on their baseline CTP scan and achieved successful endovascular reperfusion. Patients with mismatch were categorized into target mismatch and malignant mismatch profiles, according to the volume of their Tmax >10s lesion volume (target mismatch, <100 mL; malignant mismatch, >100 mL). We investigated the impact of CTP-to-reperfusion times on probability of achieving functional independence (modified Rankin Scale, 0-2) at day 90 and radiographic outcomes at day 5. RESULTS:Of 156 included patients, 108 (59%) had the target mismatch profile, and 48 (26%) had the malignant mismatch profile. In patients with the target mismatch profile, CTP-to-reperfusion time showed no association with functional independence (P=0.84), whereas in patients with malignant mismatch profile, CTP-to-reperfusion time was strongly associated with lower probability of functional independence (odds ratio, 0.08; P=0.003). Compared with patients with target mismatch, those with the malignant mismatch profile had significantly more infarct growth (90 [49-166] versus 43 [18-81] mL; P=0.006) and larger final infarct volumes (110 [61-155] versus 48 [21-99] mL; P=0.001). CONCLUSIONS:Compared with target mismatch patients, those with the malignant profile experience faster infarct growth and a steeper decline in the odds of functional independence, with longer delays between baseline imaging and reperfusion. However, this does not exclude the possibility of treatment benefit in patients with a malignant profile.

PROVIDER: S-EPMC5875452 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3104106 | BioStudies
| S-EPMC7646387 | BioStudies
| S-EPMC8189856 | BioStudies
| S-EPMC8283804 | BioStudies
2016-01-01 | S-EPMC4748242 | BioStudies
| S-EPMC7946163 | BioStudies
| S-EPMC5307934 | BioStudies
| S-EPMC6819495 | BioStudies
| S-EPMC6168913 | BioStudies
| S-EPMC3248048 | BioStudies